Supportive Oligonucleotide Therapy (SOT):
Emerging Approaches in Lyme Disease Treatment
An increasing number of patients in the community are exploring Supportive Oligonucleotide Therapy (SOT), with varied experiences and outcomes. This section is provided for informational purposes only. SOT is an emerging and evolving area of care, and ASPIRE does not provide clinical guidance or expertise on its use. Patients should discuss all treatment decisions with a qualified healthcare provider.
Key Takeaways
- Supportive Oligonucleotide Therapy (SOT) employs synthetic nucleic acids to target specific genetic sequences within pathogens, aiming to reduce their replication.
- Each pathogen and strain must be targeted individually, which may necessitate multiple treatments, particularly when co-infections are present.
- Preliminary data indicate reductions in pathogen DNA levels; however, clinical outcomes such as symptom improvement and functional gains remain insufficiently established.
- Treatment is typically individualized, requires out-of-pocket payment, and may necessitate repeated dosing.
What SOT is
Supportive Oligonucleotide Therapy (SOT), also known as antisense oligonucleotide therapy (ASOT), is an experimental approach intended to target infections at the genetic level.
SOT uses short, laboratory-synthesized strands of nucleic acid (an oligonucleotide) that bind to specific genetic sequences within a pathogen, such as Borrelia burgdorferi, the bacterium associated with Lyme disease; Epstein–Barr virus (EBV); herpes simplex virus (HSV); or cytomegalovirus (CMV). Upon binding, it blocks the production of proteins essential for the pathogen’s survival or replication, effectively disrupting its function.
This approach is part of a broader, rapidly evolving field of medicine focused on gene-targeted therapies, including antisense and RNA-based treatments that have been investigated in multiple diseases.
How SOT works
SOT is intended to silence specific genetic targets within pathogens. This process is known as gene silencing.
A common way to describe this mechanism is a “lock and key” model:
- The pathogen’s DNA or RNA contains a critical “lock”—a specific gene sequence required for replication or survival
- The SOT oligonucleotide is a precisely engineered “key,” designed to bind to that complementary sequence
- When the oligonucleotide binds to the target sequence, it blocks the production of a protein required for function
- As a result, the pathogen’s ability to replicate is impaired
In contrast to antibiotics or antivirals, which affect broader biological processes, SOT acts at a sequence-specific level by targeting a defined segment of the pathogen’s genetic code.
Antisense therapies have been successfully used in other areas of medicine. For example:
- Fomivirsen was approved for CMV retinitis (PMID: 9815174)
- Other RNA-based therapies have been approved for neurologic and genetic conditions (PMID: 29191460)
These examples provide a scientific rationale for gene-silencing approaches; however, they do not establish efficacy for Lyme disease.
What SOT does
The primary objective of SOT is to reduce pathogen activity by limiting replication.
In Lyme disease and certain viral infections:
- Targeting a critical gene sequence may decrease the pathogen’s ability to reproduce
- This reduction is expected to occur gradually rather than immediately.
Preliminary data and small clinical series have reported:
- Reductions in Borrelia burgdorferi DNA levels following one or two treatments
- Inhibition of viral replication in laboratory settings for pathogens such as HSV and EBV
Some patients have reported improvements in symptoms such as fatigue, cognitive function, or pain. However, several important considerations remain:
- Most studies focus on laboratory markers, not clinical outcomes
- The relationship between reduced DNA levels and symptom improvement is not well established
SOT has also been described as having the following characteristics:
- Extended activity (often 3–6 months per treatment)
- Continuous suppression of replication during that period
Procedure
SOT involves an individualized, multi-step process:
- Testing
- Blood testing is performed to identify active infections, often using PCR or similar methods
- Customization
- A laboratory designs an oligonucleotide targeting a specific pathogen identified in testing
- Manufacturing
- The therapy is conducted over several weeks
- Infusion
- SOT is administered as a single intravenous infusion
- Infusion typically takes 1–2 hours
- Some providers use pre-medications (e.g., antihistamines, steroids)
- Follow-Up
- Patients are monitored for response and side effects
- Repeat testing may be performed
- Additional treatments may be considered if needed
SOT may be administered repeatedly, often up to three times per year, depending on clinical response and the overall treatment plan.
Side Effects
Reported side effects are generally characterized as mild to moderate; however, comprehensive safety data remain limited.
Commonly reported reactions include:
- fatigue
- headache
- body aches
- flu-like symptoms
- Herxheimer-type (“die-off”) reactions
The timing and intensity of these reactions vary. Some individuals report minimal side effects, whereas others experience a temporary worsening of symptoms following treatment.
Currently, no large, controlled studies have defined the full safety profile of SOT in the context of Lyme disease.
Considerations and Limitations
SOT is not considered a standard or established treatment for Lyme disease. Several important limitations warrant consideration:
Limited Clinical Evidence
- Current research is limited to small-scale studies and preliminary data.
- Few studies have evaluated meaningful clinical outcomes, such as symptom improvement or functional status.
Not FDA-Approved for Lyme Disease
- Although antisense therapies are approved for other conditions, SOT has not been approved for Lyme disease or related infections.
Uncertain Clinical Benefit
- Reductions in pathogen DNA do not necessarily correspond to improvements in clinical symptoms.
- Responses to treatment are variable.
Co-Infections
- SOT targets a single pathogen at a time.
- Lyme disease is frequently associated with co-infections, such as Bartonella or Babesia, which may require separate treatment.
Variability in Response
- Some patients require multiple treatment cycles.
- Others may not experience a significant clinical benefit.
Cost and Access
- Treatment is typically paid for out-of-pocket.
- Reported costs commonly range from $1,500 to $5,000 per treatment.
Long-Term Outcomes Unknown
- Long-term safety and durability of response have not yet been established.
- Larger, well-designed clinical trials are necessary to further evaluate SOT.
Choosing a SOT Clinic
SOT is not standardized, and practices vary between clinics. Careful evaluation is important. SOT protocols, laboratory methods, and follow-up care are not uniform, which may impact outcomes.
Key considerations:
- Clinical experience: Does the provider have experience with IV therapies and treating Lyme disease and co-infections?
- Testing and targeting: What testing is used, and how are pathogens selected for treatment, given that each pathogen and strain must be targeted individually?
- Treatment approach: How is response assessed, and what is the plan if results are limited or incomplete?
- Monitoring and safety: What monitoring is done during and after infusion, and how are side effects managed?
- Cost and transparency: What are the total costs, including repeat treatments or additional targeting of co-infections?
References
- Apostolou P, Iliopoulos A, Beis G, Papasotiriou I. Supportive Oligonucleotide Therapy (SOT) as a Potential Treatment for Viral Infections and Lyme Disease: Preliminary Results. Infect Dis Rep. 2022;14(6):824–836.
- Crooke ST. Antisense Drug Technology: Principles, Strategies, and Applications. CRC Press; 2008.
- Perry CM, Balfour JA. Fomivirsen. Drugs. 1999;57(3):375–380. PMID: 10080450.
- Stein CA, Castanotto D. FDA-Approved Oligonucleotide Therapies. Mol Ther. 2017;25(5):1069–1075. PMID: 28457632.
- Kole R, Krainer AR, Altman S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 2012;11(2):125–140. PMID: 22262067.
- Khorkova O, Wahlestedt C. Oligonucleotide therapies for CNS disorders. Neurotherapeutics. 2017;14(4):827–840. PMID: 29191460.
- Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides. Nucleic Acids Res. 2010;38(1):e3. PMID: 19850725.
Gabriella True
